Trastuzumab (HLX02) plus Pertuzumab as Dualtarget Neoadjuvant Therapy for HER2-positive Breast Cancer: A Real-World Study

被引：0
|
作者：
Liu, Yin
Zuo, Wen-Jia
Wang, Ruo-Xi
Wang, Zhong-Hua
Shao, Zhi-Ming
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
基金：
上海市自然科学基金;
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-11-20
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-20
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
    Veeraraghavan, Jamunarani
    Gutierrez, Carolina
    Sethunath, Vidyalakshmi
    Mehravaran, Sepideh
    Giuliano, Mario
    Shea, Martin J.
    Mitchell, Tamika
    Wang, Tao
    Nanda, Sarmistha
    Pereira, Resel
    Davis, Robert
    Goutsouliak, Kristina
    Qin, Lanfang
    De Angelis, Carmine
    Diala, Irmina
    Lalani, Alshad S.
    Nagi, Chandandeep
    Hilsenbeck, Susan G.
    Rimawi, Mothaffar F.
    Osborne, C. Kent
    Schiff, Rachel
    NPJ BREAST CANCER, 2021, 7 (01)
  • [22] Pertuzumab plus trastuzumab increases survival in patients with HER2-positive breast cancer
    Mayor, Susan
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2014, 75 (11) : 611 - 611
  • [23] Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
    Jamunarani Veeraraghavan
    Carolina Gutierrez
    Vidyalakshmi Sethunath
    Sepideh Mehravaran
    Mario Giuliano
    Martin J. Shea
    Tamika Mitchell
    Tao Wang
    Sarmistha Nanda
    Resel Pereira
    Robert Davis
    Kristina Goutsouliak
    Lanfang Qin
    Carmine De Angelis
    Irmina Diala
    Alshad S. Lalani
    Chandandeep Nagi
    Susan G. Hilsenbeck
    Mothaffar F. Rimawi
    C. Kent Osborne
    Rachel Schiff
    npj Breast Cancer, 7
  • [24] Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study
    Fabbri, M. A.
    Botticelli, A.
    Omarini, C.
    Cretella, E.
    Fabi, A.
    Alesini, D.
    Pizzuti, L.
    Piesco, G.
    Vaccaro, A.
    Atzori, F.
    Piacentini, F.
    Moscetti, L.
    Orlandi, A.
    Sini, V.
    Mercanti, A.
    Framarino, M. L.
    Persano, M.
    Ceccherini, R.
    Ruggeri, E. M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China
    Deng, Weishang
    Hu, Jia
    Li, Mengting
    Yang, Sensen
    Xie, Zeyu
    Chen, Jisheng
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (07) : 1117 - 1126
  • [26] Real-world data of subcutaneous trastuzumab and intravenous pertuzumab as neoadjuvant therapy for localized HER2+ breast cancer in Panama
    Rodriguez, Franklin Castillero
    Castillo-Fernandez, Omar
    Lim-Law, Maria
    Palacios, Cristiane Martin
    Montano, Lilian
    Benitez, Stephanie
    Samudio, Jaime
    BREAST CANCER MANAGEMENT, 2021, 10 (01)
  • [27] A cases of pertuzumab plus trastuzumab plus docetaxel was effective for inflammatory breast cancer with HER2-positive
    Yamashita, Yuji
    Tanaka, Yuko
    Nishimura, Meiko
    Mukohara, Toru
    Kono, Seishi
    Takao, Shintaro
    Minami, Hironobu
    ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [28] Neoadjuvant trastuzumab and pertuzumab in combination with anthracyclines in HER2-positive early breast cancer: real-world data on effect of body mass index in cardiac safety
    Simao, Diana
    Sardinha, Mariana
    Gil, Lucia
    Montenegro, Alexandra
    Mendes, Jose
    Fernandes, Leonor
    Winckler, Patricia
    Luz, Ricardo
    Oliveira, Sonia
    CANCER RESEARCH, 2023, 83 (05)
  • [29] Updated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trial
    Xu, Binghe
    Zhang, Qingyuan
    Sun, Tao
    Li, Wei
    Teng, Yue'e
    Hu, Xichun
    Bondarenko, Igor
    Adamchuk, Hryhoriy
    Zhang, Liangming
    Trukhin, Dmytro
    Wang, Shusen
    Zheng, Hong
    Tong, Zhongsheng
    Shparyk, Yaroslav
    Yang, Futang
    Yu, Haoyu
    Li, Jing
    Wang, Qingyu
    Zhu, Jun
    BREAST, 2025, 80
  • [30] Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study
    Wang, B.
    You, S.
    Xie, Y.
    Xu, F.
    Sang, D.
    Luo, T.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S361 - S362
12345